Conference Proceedings
THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study.
Filip Janku, Raghad Abdul-Karim, Arun Azad, Johanna Bendell, Gerald Falchook, Hui K Gan, Tira Tan, Judy S Wang, Cheng Ean Chee, Lina Ma, Jill Mooney, Neyssa Marina, Giovanni Abbadessa, Marcos Milla, Tarek Meniawy
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2021
Abstract
Abstract THOR-707 (SAR444245) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to block the alpha-binding domain while retaining near-native affinity for the beta/gamma subunits. In animal models, THOR-707 improved the anti-tumor benefits of aldesleukin, but without its severe side effects, both as single agent and combined with anti-PD1. Here we report safety, PK/PD, and preliminary anti-tumor activity for THOR-707 as monotherapy and combined with pembrolizumab in the ongoing HAMMER Phase 1/2 trial. THOR-707 was administered via IV infusion as monotherapy Q2W (Cohort A), Q3W (Cohort B),..
View full abstract